Amplitude Therapeutics and Lilly Enter Strategic Collaboration to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases
Research collaboration combines Amplitude's proprietary taRNA with Lilly's global development, manufacturing, and commercialization capabilities Initial programs target infectious diseases with high unmet need, with Lilly retaining options for up to two additional targets BOSTON, Aug. 19,...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.